In: NEOPLASMA, vol. 52, no. 5
M. Doubek - I. Palasek - Y. Brychtova - I. Buchtova - J. Mayer
Detaily:
Rok, strany: 2005, 411 - 414
O článku:
State-of-art of aggressive treatment of acute myeloid leukemia
(AML) in patients older than 60 years is one of the least
satisfactory topics of present-day hematology.
This fact led us to ask the following questions: Does it make
sense to administer aggressive treatment to older patients
with AML? Could it be that we only complicate the rest of the life
of these older patients with AML, by using aggresive
treatment? Would they not benefit more from palliative or
symptomatic therapy? What is the quality of life of older patients
with AML like? Therefore, to try to answer these questions, we
performed the next analysis.
A retrospective analysis was performed including (without any
selection) all consecutive patients over 60 years of age
who were treated with AML in our centre from 1998 till 2003.
We have analyzed data from 137 elderly patients who were diagnosed
with AML (excluding acute promyelocytic leukemia).
Median survival from diagnosis in the aggressive (curative)
therapy group was 4 months, in palliative therapy group
2 months and in symptomatic therapy group 0.8 months. Patients
receiving curative therapy spent in a hospital (in-patient
stay) 70% (median) of their life after diagnosis of AML, patients
receiving palliative treatment 64% (median) of their life after
diagnosis, and patients receiving symptomatic treatment 100%
(median), respectively.
Only marginal advantage in the median overall survival is observed
in the group of aggressively treated patients.
Ako citovať:
ISO 690:
Doubek, M., Palasek, I., Brychtova, Y., Buchtova, I., Mayer, J. 2005. Acute myeloid leukemia treatment in patients over 60 years of age. Comparison of symptomatic, palliative, and aggressive therapy. In NEOPLASMA, vol. 52, no.5, pp. 411-414. 0028-2685.
APA:
Doubek, M., Palasek, I., Brychtova, Y., Buchtova, I., Mayer, J. (2005). Acute myeloid leukemia treatment in patients over 60 years of age. Comparison of symptomatic, palliative, and aggressive therapy. NEOPLASMA, 52(5), 411-414. 0028-2685.